Spero Therapeutics

At , it is our hope to advance for and MDR .

Since our inception in 2013, we have been steadfast in our to superior approaches for bacterial infections. Our founding was a response to the urgent need to combat severe infections and the escalating crisis of . Our pipeline targets areas where approved therapies are scarce, or where the prevailing of care are suboptimal.